article thumbnail

Clinical Study Highlights Research on AI that Takes on Cardiopulmonary Killer

DAIC

6, 2025 Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, recently announcedpublication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH). tim.hodson Mon, 02/10/2025 - 12:43 Feb.

article thumbnail

NYC Health + Hospitals receives 3rd award for hypertension care

Becker's Hospital Review - Cardiology

NYC Health + Hospitals has for a third time received an award from HHS for its innovative hypertension care. The New York City public health system is one of 11 organizations in the nation to be recognized, according to a June 5 news release from the system.

article thumbnail

Mitophagy in hypertension-mediated organ damage

Frontiers in Cardiovascular Medicine

Hypertension constitutes a pervasive chronic ailment on a global scale, frequently inflicting damage upon vital organs, such as the heart, blood vessels, kidneys, brain, and others. In recent years, research has increasingly shown that mitophagy plays an important role in organ damage associated with hypertension.

article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Data Demonstrates Favorable Impact of AVIM Therapy on Diastolic Dysfunction

DAIC

The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (Echo) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients. Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed.

article thumbnail

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat

DAIC

a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. We believe suppression of aldosterone production by lorundrostat has the potential to reduce the nocturnal hypertension driving adverse cardiovascular outcomes.

article thumbnail

Harnessing Telehealth and Home Blood Pressure Monitoring to Improve Hypertension Care

Cardiometabolic Health Congress

Hypertension is a condition that requires continuous monitoring, making it an ideal candidate for telehealth and digital health innovations. Why Telehealth is Essential for Hypertension For patients with hypertension, managing blood pressure outside of the office is crucial. Who Should Use Video Visits?